Last reviewed · How we verify
Single Dose of VU319
Single Dose of VU319 is a Small molecule drug developed by Vanderbilt University. It is currently in Phase 1 development.
At a glance
| Generic name | Single Dose of VU319 |
|---|---|
| Sponsor | Vanderbilt University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Putative Cognitive Enhancer VU319 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single Dose of VU319 CI brief — competitive landscape report
- Single Dose of VU319 updates RSS · CI watch RSS
- Vanderbilt University portfolio CI
Frequently asked questions about Single Dose of VU319
What is Single Dose of VU319?
Single Dose of VU319 is a Small molecule drug developed by Vanderbilt University.
Who makes Single Dose of VU319?
Single Dose of VU319 is developed by Vanderbilt University (see full Vanderbilt University pipeline at /company/vanderbilt-university).
What development phase is Single Dose of VU319 in?
Single Dose of VU319 is in Phase 1.
Related
- Manufacturer: Vanderbilt University — full pipeline
- Compare: Single Dose of VU319 vs similar drugs
- Pricing: Single Dose of VU319 cost, discount & access